The DOI matches its Crossref record.
Imiquimod and resiquimod as novel immunomodulators
Abstract
Augmenting the host's natural immune response to viruses by the administration of exogenous cytokines such as interferon-alpha (IFN-alpha) is a strategy increasingly employed in antiviral therapeutics. Enhancing the release of endogenous cytokines is, however, an alternative approach. The imidazoquinolinamines imiquimod and resiquimod have demonstrated potency as inducers of IFN-alpha and other cytokines both in vitro and in vivo. Cytokine gene activation is mediated via the signal transducer and activator of transcription 1 (STAT-1) and involves the transcription factors NFkappaB and alpha4F1. Antiviral activity has been demonstrated against a variety of viruses, and clinical efficacy has been demonstrated against genital warts, herpes genitalis and molluscum contagiosum. Imiquimod is administered as a 5% cream (Aldara) and has been licensed for the treatment of anogenital warts in immunocompetent patients. Complete clearance of warts has been observed in up to half of treated patients with only local side effects reported. Resiquimod can be administered topically but also exists as an oral formulation. The range of potential infections for which these agents may have clinical utility includes chronic hepatitis C virus infection and Kaposi's sarcoma. In addition, the imidazoquinolinamines may find roles in the therapy of cancers and as vaccine adjuvants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T.-D., Özören, N., Body-Malapel, M., Amer, A., Park, J.-H., Franchi, L., Whitfield, J., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,148
Immunopathogenesis and therapy of cutaneous T cell lymphoma
Kim, E. J., Hess, S., Richardson, S. K., Newton, S., Showe, L. C., Benoit, B. M., Ubriani, R., Vittorio, C. C., Junkins-Hopkins, J. M., Wysocka, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24826 · Cited by 413
Caron, G., Duluc, D., Frémaux, I., Jeannin, P., David, C., Gascan, H., & Delneste, Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1551 · Cited by 410
Kulka, M., Alexopoulou, L., Flavell, R. A., & Metcalfe, D. D. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.049 · Cited by 351
Schön, M. P., & Schön, M. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08265.x · Cited by 346
Metadata
- Authors
- Dockrell, D. H.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-12-01
- Volume
- 48
- Issue
- 6
- Pages
- 751-755
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W1986031713
- Cited by
- 185
- References
- 0
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imiquimod and resiquimod as novel immunomodulators. https://app.cochat.ai/papers/10.1093/jac/48.6.751
- The paper
- Dockrell, D. H. (2001). Imiquimod and resiquimod as novel immunomodulators. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/48.6.751
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.